CG Oncology (CGON) Total Non-Current Liabilities (2023 - 2026)

CG Oncology has reported Total Non-Current Liabilities for 4 years, with the latest figure at $42.0 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities changed N/A year-over-year to $42.0 million; the trailing twelve-month figure through Mar 2026 stood at $42.0 million (changed N/A YoY), and the FY2025 full-year result was $37.2 million, up 73.9% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $42.0 million, up from $37.2 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $42.0 million in Q1 2026, with the low at $14.1 million in Q4 2023.
• Historically, Total Non-Current Liabilities has averaged $30.7 million across 4 years, with a median of $37.2 million in 2025.
• Annual changes were most pronounced in 2024 — Total Non-Current Liabilities soared 51.42% — and 2025, when it jumped 73.9%.
• CG Oncology's Total Non-Current Liabilities stood at $14.1 million in 2023, then jumped by 51.42% to $21.4 million in 2024, then jumped by 73.9% to $37.2 million in 2025, then grew by 12.84% to $42.0 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $42.0 million (Q1 2026), $37.2 million (Q4 2025), and $38.5 million (Q3 2025), per Business Quant data.